B+
Bull case
30%
Probability
Target price
$880.00
+46.0% vs current
REGN
RegeneronCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$780.00
+29.4% vs current
B-
Bear case
25%
Probability
Target price
$620.00
+2.8% vs current
AI sentiment snapshot
Latest data as of 2026-04-29
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+77.0
Score
AI commentary
This is a high-buzz T+1 earnings setup with a mixed tone: recent trusted-news headlines in the packet describe both an earnings beat and a share-price slide as investors focused on EYLEA pressure and the gross-margin outlook. Immediate post-print analyst revision evidence is not reliably available in the packet, and the peer set is too broad to support a standard-conviction relative-value call, so the memo should remain a tentative monitoring view rather than a bullish re-rate thesis.
RankAlpha Sentiment Codex - 2026-04-29
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; memo remains a monitoring view with limited forward evidence and should not be standard-conviction
Impact
tentative
Confidence
-
AI events
2026-04-29eventQ1 beat offset by EYLEA mix pressure and lower gross-margin outlookMedium impact
Regeneron reported Q1 2026 revenue up 19% to $3.6 billion and non-GAAP EPS of $9.47, while total U.S. EYLEA HD plus EYLEA sales fell 10% year over year to $941 million. Management also lowered 2026 GAAP gross-margin guidance to 77%-78% from 79%-80% because of the temporary Limerick manufacturing interruption, which is expected to normalize by the end of Q2 2026. This keeps the earnings print mixed rather than cleanly bullish. [#8-K-2026-04-29] [#10-Q-2026-04-29]
2026-09-30catalystEYLEA HD conversion must outgrow legacy EYLEA erosionHigh impact
EYLEA HD U.S. sales rose 52% to $468 million and physician unit demand increased sequentially by 10%, helped by expanded dosing flexibility, but legacy EYLEA declined 36% and the company warned additional U.S. biosimilar competition is expected in the second half of 2026. The key medium-term question is whether EYLEA HD uptake can offset erosion across the broader retina franchise. [#10-Q-2026-04-29]
2026-12-31catalystDupixent and Libtayo strength continues to fund pipeline and buybacksHigh impact
Sanofi-recorded Dupixent global net sales increased 33% to $4.9 billion and Regeneron said its share of antibody commercialization profits rose to $1.451 billion, while global Libtayo sales increased 54% to $438 million. Alongside $18.5 billion of cash and marketable securities and a new $3.0 billion repurchase authorization, these franchises support ongoing late-stage investment even as retina pressure persists. [#8-K-2026-04-29] [#10-Q-2026-04-29]
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-29 • Updated nightlySource: Internal modelMethodology